

Switching

Physicians can safely guide the switch from a reference medicine to a biosimilar.



A biosimilar is developed to match its reference medicine and is approved as having no clinically meaningful differences in terms of safety, efficacy, and quality.^{1,2}



Under the guidance of a physician - with a treating physician being the best suited individual to make this decision - patients treated with a reference medicine can be safely switched to a biosimilar.



**Reference
medicine**



Biosimilar

SANDOZ A Novartis
Division



**Sandoz, a Novartis division,
believes the patient's
physician is best suited to
make decisions about their
treatment.**

1. McCamish M et al. Clin. Pharmacol. Ther. 2015, 97(3): 215-217
2. Kurki P et al. Biodrugs. 2017, 31(2): 83-91